ArticleBrain : a journal of neurology2025
Novel modelling approaches to elucidate the genetic architecture of resilience to Alzheimer's disease.
Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetics of educational resilience after adverse childhood experiences.EBioMedicine · 2026Article
- A new ANMerge-based blood transcriptomic resource to support Alzheimer's disease research.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors.
Funding
Abstract
Up to 30% of older adults meet pathological criteria for a diagnosis of Alzheimer's disease at autopsy yet never show signs of cognitive impairment. Recent work has highlighted genetic drivers of this resilience, or better-than-expected cognitive performance given a level of neuropathology, that allow the aged brain to protect itself from the downstream consequences of amyloid and tau deposition. However, models of resilience have been constrained by reliance on measures of neuropathology, substantially limiting the number of participants available for analysis. We sought to determine whether new approaches using APOE allele status, age and other demographic variables as a proxy for neuropathology could still effectively quantify resilience and uncover novel genetic drivers associated with better-than-expected cognitive performance while vastly expanding sample size and statistical power. Leveraging 20 513 participants from eight well-characterized cohort studies of ageing, we determined the effects of genetic variants on resilience metrics using mixed-effects regressions. The outcome of interest was residual cognitive resilience, quantified from residuals in three cognitive domains (memory, executive function and language) and built within two frameworks: 'silver' models, which obviate the requirement for neuropathological data (n = 17 241), and 'gold' models, which include post-mortem neuropathological assessments (n = 3272). We then performed cross-ancestry genome-wide association studies (European ancestry, n = 18 269; African ancestry, n = 2244), gene- and pathway-based tests and genetic correlation analyses. All analyses were conducted across all participants and repeated when restricted to those with unimpaired cognition at baseline. Despite different modelling approaches, the silver and gold phenotypes were highly correlated (R = 0.77-0.88) and displayed comparable performance in quantifying better- or worse-than-expected cognition, enabling silver-gold meta-analyses. Genetic correlation analyses highlighted associations of resilience with multiple neuropsychiatric and cardiovascular traits [false discovery rate-corrected P (PFDR) values < 5.0 × 10-2]. In pathway-level tests, we observed three significant associations with resilience: metabolism of amino acids and derivatives (PFDR = 4.1 × 10-2), negative regulation of transforming growth factor beta (TGF-β) production (PFDR = 1.9 × 10-2) and severe acute respiratory syndrome (PFDR = 3.9 × 10-4). Finally, in single-variant analyses, we identified a locus on chromosome 17 approaching genome-wide significance among cognitively unimpaired participants (index single nucleotide polymorphism: rs757022, minor allele frequency = 0.18, β=0.08, P = 1.1 × 10-7). The top variant at this locus (rs757022) was significantly associated with expression of numerous ATP-binding cassette genes in brain. Overall, through validating a novel modelling approach, we demonstrate the utility of silver models of resilience to increase statistical power and participant diversity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.